---
title: "Avalyn Sets IPO Price At $18 Per Share"
type: "News"
locale: "en"
url: "https://longbridge.com/en/news/284722135.md"
description: "Avalyn Pharma Inc. has set its IPO price at $18 per share for its upcoming trading on the Nasdaq under the ticker \"AVLN\" starting April 30, 2026. The company plans to offer 16.67 million shares, aiming for gross proceeds of $300 million, with the offering closing on May 1, 2026."
datetime: "2026-04-30T08:07:21.000Z"
locales:
  - [zh-CN](https://longbridge.com/zh-CN/news/284722135.md)
  - [en](https://longbridge.com/en/news/284722135.md)
  - [zh-HK](https://longbridge.com/zh-HK/news/284722135.md)
---

# Avalyn Sets IPO Price At $18 Per Share

Add  as your preferred news source on Google

 Add Now

Avalyn Pharma Inc., a clinical-stage biopharmaceutical company pioneering inhaled therapies for treating pulmonary fibrosis, is set to begin trading on the Nasdaq Global Select Market under the ticker symbol "AVLN" on **April 30, 2026**.

The company has priced its upsized initial public offering of 16.67 million shares of its common stock at $18.00 per share. The offering is scheduled to close on May 1, 2026, and gross proceeds to Avalyn are expected to be $300 million.

This article is part of our premium content offering.Subscribe with a RTTNews subscription.

Subscribe Now

Already subscribed? Sign in

For comments and feedback contact: editorial@rttnews.com

Business News

### Related Stocks

- [IBB.US](https://longbridge.com/en/quote/IBB.US.md)
- [IHF.US](https://longbridge.com/en/quote/IHF.US.md)
- [SBIO.US](https://longbridge.com/en/quote/SBIO.US.md)
- [BMED.US](https://longbridge.com/en/quote/BMED.US.md)
- [BIB.US](https://longbridge.com/en/quote/BIB.US.md)
- [FBT.US](https://longbridge.com/en/quote/FBT.US.md)
- [BBH.US](https://longbridge.com/en/quote/BBH.US.md)
- [513290.CN](https://longbridge.com/en/quote/513290.CN.md)
- [LABU.US](https://longbridge.com/en/quote/LABU.US.md)
- [TMED.US](https://longbridge.com/en/quote/TMED.US.md)
- [XLV.US](https://longbridge.com/en/quote/XLV.US.md)
- [BIS.US](https://longbridge.com/en/quote/BIS.US.md)
- [IXJ.US](https://longbridge.com/en/quote/IXJ.US.md)
- [PBE.US](https://longbridge.com/en/quote/PBE.US.md)
- [XBI.US](https://longbridge.com/en/quote/XBI.US.md)
- [VHT.US](https://longbridge.com/en/quote/VHT.US.md)
- [ARKG.US](https://longbridge.com/en/quote/ARKG.US.md)
- [IHE.US](https://longbridge.com/en/quote/IHE.US.md)
- [IBBQ.US](https://longbridge.com/en/quote/IBBQ.US.md)
- [NDAQ.US](https://longbridge.com/en/quote/NDAQ.US.md)

## Related News & Research

- [Enanta Pharma's RSV Bet And Immunology Ambitions](https://longbridge.com/en/news/286895623.md)
- [14:05 ETLupin Receives Tentative Approval from U.S. FDA for Revefenacin Inhalation Solution](https://longbridge.com/en/news/286805922.md)
- [Artiva says AB-101 plus rituximab posts 71% ACR50 response in refractory RA study](https://longbridge.com/en/news/286959967.md)
- [Relay's treatment shown to shrink vascular malformations in mid-stage trial](https://longbridge.com/en/news/286890329.md)
- [Sanofi says rare lung disease drug outperforms standard care in trial](https://longbridge.com/en/news/286810610.md)